Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Development of resistance to endocrine therapy is a clinical issue in estrogen receptor (ER)-positive breast cancer. Here we show that persistent activation of AKT/mTOR signaling is crucial to the acquisition of letrozole resistance in cell clones generated from MCF-7/AROM-1 aromatase-expressing breast cancer cells after prolonged letrozole exposure. ERα plays a marginal role in this context. As a proof of concept, the association between PI3K/AKT/mTOR signaling and insensitivity to endocrine therapies was confirmed in breast cancer patients who developed early letrozole resistance in neoadjuvant setting. In addition our results suggest that, regardless of the mechanism mediating the activation of AKT/mTOR pathway, either RAD001 or NVP-BEZ235 treatment may represent a promising strategy to overcome acquired resistance to letrozole in breast cancers dependent on AKT/mTOR signaling.

Original publication




Journal article


Cancer Lett

Publication Date





77 - 87


Aged, Antineoplastic Agents, Blotting, Western, Breast Neoplasms, Cell Line, Tumor, Drug Resistance, Neoplasm, Everolimus, Female, Humans, Imidazoles, Immunosuppressive Agents, Letrozole, Neoadjuvant Therapy, Nitriles, Phosphatidylinositol 3-Kinases, Proto-Oncogene Proteins c-akt, Quinolines, Signal Transduction, Sirolimus, TOR Serine-Threonine Kinases, Triazoles